Tandem Diabetes SEC Filings

Tandem Diabetes Care Inc. reported an insider equity transaction by its Chief Technology Officer, Rick A. Carpenter. On 12/15/2025, 406 restricted stock units (RSUs) granted on 12/15/2021 under the company’s 2013 Stock Incentive Plan were converted into common stock at an exercise price of $0.

To cover tax withholding on the RSU vesting, the company withheld 207 shares at a price of $22.11 per share, and no shares were sold on the open market. After these transactions, Carpenter directly holds 24,252 shares of Tandem Diabetes Care common stock.

Tandem Diabetes Care, Inc. (TNDM) reported an equity award to one of its directors on a Form 4. The director received 20,242 restricted stock units (RSUs) on November 7, 2025 under the company’s 2023 Long-Term Incentive Plan.

Each RSU represents a right to receive either one share of Tandem’s common stock or cash, at the company’s discretion, subject to the plan’s terms. The RSUs vest as to 33% of the total award on November 15, 2026, with the remaining units vesting in two equal annual installments after that date, contingent on the applicable conditions being met.

Tandem Diabetes Care, Inc. director Sandra Beaver filed an initial statement of beneficial ownership of securities. As of the event date of 11/07/2025, the filing reports beneficial ownership of 0 shares of common stock of Tandem Diabetes Care, Inc., held directly. The filing also shows no derivative securities, such as options or warrants, currently reported as beneficially owned.

Tandem Diabetes Care Inc. (TNDM) reported equity compensation activity for an executive officer. The EVP & Chief Administrative Officer had restricted stock units (RSUs) convert into common stock on 11/17/2025, with 1,503 and 1,096 RSUs settled into shares at an exercise price of $0.

To cover tax withholding on these vestings, the company withheld 430 and 314 shares at a price of $18.61 per share, and no shares were sold into the market. Following these transactions, the reporting person directly beneficially owned around forty thousand shares of Tandem Diabetes Care common stock.

Tandem Diabetes Care Inc. (TNDM) reported insider equity activity by President & CEO and director John F. Sheridan. On 11/17/2025, restricted stock units (RSUs) granted under the company’s 2023 Long-Term Incentive Plan vested and were settled into common stock at no exercise price.

Following the vesting, 5,472 RSUs and 5,982 RSUs were converted into an equal number of common shares. To cover tax withholding on these RSU vestings, the company withheld 2,779 shares and 3,038 shares at a reference price of $18.61 per share; the filing states that no shares were sold. After these transactions, Sheridan directly owned 117,600 shares of common stock, plus 10,943 RSUs and 35,894 RSUs that remain outstanding and subject to the plan’s vesting schedule.

Tandem Diabetes Care (TNDM) executive vice president and chief strategy officer Elizabeth A. Gasser reported several equity transactions in the company’s stock. She voluntarily disclosed acquiring 586 shares of common stock at $15.59 through the company’s Employee Stock Purchase Plan for the May 16, 2025 to November 17, 2025 purchase period.

On the same date, 1,503 and 1,096 shares of common stock were delivered upon the vesting of previously granted restricted stock units, at an exercise price of $0. To cover tax withholding on these RSU vestings, the company withheld 805 and 587 shares at a price of $18.61 per share; no shares were sold into the market.

Following these transactions, Gasser directly beneficially owns 3,000 shares of Tandem Diabetes Care common stock and indirectly beneficially owns 22,949 shares through The Gasser Family Trust dated September 1, 2011, where she serves as co-trustee. The RSUs were granted under the company’s 2023 Long-Term Incentive Plan and vest over multi-year schedules.

Tandem Diabetes Care (TNDM) Chief Technology Officer Rick A. Carpenter reported several equity transactions involving company stock. He voluntarily disclosed acquiring 339 shares of common stock at $15.59 per share through the company’s Employee Stock Purchase Plan for the period from May 16, 2025 through November 17, 2025.

On the same date, 1,437 and 897 restricted stock units (RSUs) were converted into common shares at a $0 exercise price under the 2023 Long-Term Incentive Plan. To cover taxes on these RSU vestings, the company withheld 730 and 456 shares at a price of $18.61 per share, with no shares sold on the market. After these transactions, Carpenter directly beneficially owned 24,053 shares of Tandem Diabetes Care common stock.

Tandem Diabetes Care Inc. (TNDM) reported an insider equity transaction by its EVP & Chief Commercial Officer on a Form 4. On 11/17/2025, 76 restricted stock units (RSUs) were converted to common stock at an exercise price of $0, and 40 shares of common stock were withheld at $18.61 per share to cover tax obligations, with no shares sold on the market. Following these transactions, the officer beneficially owned 32,384 shares of common stock directly and 457 RSUs, subject to the company’s 2023 Long-Term Incentive Plan and a vesting schedule that runs in quarterly installments after an initial vesting on 5/15/2025.

Tandem Diabetes Care, Inc. (TNDM) executive vice president and chief operating officer Jean-Claude Kyrillos reported a routine purchase of company stock. On 11/17/2025, he acquired 160 shares of common stock at a price of $15.59 per share through the Tandem Diabetes Care Inc. Amended and Restated 2013 Employee Stock Purchase Plan for the ESPP purchase period from May 16, 2025 through November 17, 2025. Following this transaction, he beneficially owned 22,544 shares of Tandem Diabetes Care common stock held directly. The transaction is reported as exempt under Rule 16b-3(c), which typically covers certain employee benefit plan-related acquisitions.